Literature DB >> 22864187

Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation.

Abby B Siegel1, Emerson A Lim, Shuang Wang, William Brubaker, Rosa D Rodriguez, Abhishek Goyal, Judith S Jacobson, Dawn L Hershman, Elizabeth C Verna, Jonah Zaretsky, Karim Halazun, Lorna Dove, Robert S Brown, Alfred I Neugut, Tomoaki Kato, Helen Remotti, Yael J Coppleson, Jean C Emond.   

Abstract

UNLABELLED: For many cancers, features of the metabolic syndrome, such as diabetes and obesity, have been associated with both increased risk of cancer development and poor outcomes.
METHODS: We examined a large retrospective cohort of 342 consecutive patients who underwent liver transplantation for hepatocellular carcinoma between January 1999 and July 2010 at our institution. We evaluated the relationship between diabetes, obesity, hepatocellular carcinoma (HCC) recurrence, and overall survival.
RESULTS: We found that a body mass index (BMI) higher than 30 was an independent predictor of poor overall survival in a multivariable Cox model, approximately doubling the risk of death after transplantation. A BMI higher than 30 was also a predictor of recurrent HCC, although this was of borderline statistical significance (hazard ratio for recurrence, 1.9; 95% confidence interval, 0.9-4.1). We also found increased BMI to be an independent predictor of microvascular invasion within HCC tumors, lending a possible explanation to these results. Those with diabetes showed worsened overall survival compared with those without diabetes in univariate but not multivariable analysis, possibly related to longer wait times.
CONCLUSIONS: Our findings suggest a relationship between higher BMI, tumor vascular invasion, increased recurrence, and worsened overall survival. These findings may help explain why those with high BMI have worse outcomes from their cancers. A better understanding of the role of obesity and diabetes in patients with cancer should help develop better predictors of outcome and improved treatment options for patients with HCC.

Entities:  

Mesh:

Year:  2012        PMID: 22864187      PMCID: PMC3605709          DOI: 10.1097/TP.0b013e31825c58ea

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  19 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.

Authors:  K D S Watt; R A Pedersen; W K Kremers; J K Heimbach; M R Charlton
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

3.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

4.  Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score.

Authors:  Andrew L Samuelson; Maximilian Lee; Ahmad Kamal; Emmet B Keeffe; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2010-05-14       Impact factor: 3.199

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.

Authors:  Shu-Guang Li; Zai-Yuan Ye; Zhong-Sheng Zhao; Hou-Quan Tao; Yuan-Yu Wang; Chun-Yu Niu
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 7.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

8.  Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma?

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

9.  Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters.

Authors:  Mitsuro Kanda; Shuji Nomoto; Yoko Nishikawa; Hiroaki Sugimoto; Naohito Kanazumi; Shin Takeda; Akimasa Nakao
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

10.  Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis.

Authors:  Yusuke Kawamura; Kenji Ikeda; Yasuji Arase; Hiromi Yatsuji; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  J Gastroenterol Hepatol       Date:  2008-08-17       Impact factor: 4.029

View more
  26 in total

1.  Pretransplant diabetes mellitus predicts worse outcomes of liver transplantation: evidence from meta-analysis.

Authors:  P Li; H Fan; Q He
Journal:  J Endocrinol Invest       Date:  2017-06-30       Impact factor: 4.256

2.  Impact of body mass index on outcomes of 48281 patients undergoing first time cadaveric liver transplantation.

Authors:  Subhashini Ayloo; Scott Hurton; Matthew Cwinn; Michele Molinari
Journal:  World J Transplant       Date:  2016-06-24

3.  Metabolic disorders, non-alcoholic fatty liver disease and major liver resection: an underestimated perioperative risk.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Vassilis Constantinides; Claude Smadja
Journal:  J Gastrointest Surg       Date:  2012-10-09       Impact factor: 3.452

4.  Surgical outcomes in patients with hepatocellular carcinoma associated with metabolic syndrome.

Authors:  Naoki Yoshida; Tadatoshi Takayama; Yutaka Midorikawa; Tokio Higaki; Hisashi Nakayama; Masamichi Moriguchi; Shingo Tsuji
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

5.  β-cell function prior to liver transplantation contributes to post-operative diabetes.

Authors:  Tatsuki Ichikawa; Naota Taura; Hisamitsu Miyaaki; Satoshi Miuma; Hidetaka Shibata; Takuya Honda; Masaaki Hidaka; Akihiko Soyama; Mitsuhisa Takatsuki; Susumu Eguchi; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2016-10-21

Review 6.  Obesity and Energy Balance in GI Cancer.

Authors:  Justin C Brown; Jeffrey A Meyerhardt
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

Review 7.  Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.

Authors:  Xiang-Qian Gu; Wei-Ping Zheng; Da-Hong Teng; Ji-San Sun; Hong Zheng
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

8.  Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence.

Authors:  Abby B Siegel; Hashem B El-Serag
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-08       Impact factor: 3.869

Review 9.  Primary hepatocellular carcinoma and metabolic syndrome: An update.

Authors:  Rubayat Rahman; Ghassan M Hammoud; Ashraf A Almashhrawi; Khulood T Ahmed; Jamal A Ibdah
Journal:  World J Gastrointest Oncol       Date:  2013-09-15

10.  Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.

Authors:  Abby B Siegel; Abhishek Goyal; Marcela Salomao; Shuang Wang; Valerie Lee; Christine Hsu; Rosa Rodriguez; Dawn L Hershman; Robert S Brown; Alfred I Neugut; Jean Emond; Tomoaki Kato; Benjamin Samstein; David Faleck; Raffi Karagozian
Journal:  Oncology       Date:  2014-10-03       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.